C Michael Gibson/Baim Institute
Feb 7, 2026, 14:25
C Michael Gibson: Asundexian Reduces Ischemic Stroke Without Increasing Bleeding Risk
C Michael Gibson, President and CEO at Baim Institute for Clinical Research, shared on LinkedIn:
”Among patients with non-cardioembolic ischemic stroke or high-risk TIA treated with antiplatelet therapy, asundexian 50 mg reduced the occurrence of ischemic stroke (csHR 0.74; 95% CI, 0.65 to 0.84; p<0.001).
The difference between the treatment arms began early and continued throughout the treatment period.
A consistent effect was seen in subgroups.
Asundexian was associated with a reduction in disabling or fatal stroke (mRS ≥ 3)
Asundexian was not associated with an increase in bleeding Including ISTH major, CRNM, minor or intracranial bleeding.”
Stay updated with Hemostasis Today.
-
Aug 14, 2026, 16:39Yuriy Prokopenko: Advancing Hemostasis Through Scientific Collaboration
-
Aug 14, 2026, 16:26Antonio Paul: The Best Transfusion Is the One That Isn’t Needed
-
Aug 14, 2026, 16:24Thirunavukkarasu Angappan: What mRNA Manufacturing Teaches Us About Scaling Hemophilia Gene Therapy
-
Aug 14, 2026, 16:16Priyanka Raheja: Advancing Multidisciplinary Care for Women with Bleeding Disorders
-
Aug 14, 2026, 16:09Cristina Chang: Hemophilia B Gene Therapy BBM-H901 Approved in Macao
-
Aug 14, 2026, 16:03Muhammad Shaheer Bin Faheem: The Growing Mortality Divide in Thromboembolism and Hypertension
-
Aug 14, 2026, 15:53Peter Jaworski: Plasma Donation Myths and Why Plasma Matters
-
Aug 14, 2026, 15:50John Strouse: Why Older Adults with Sickle Cell Disease Should Be Included in Clinical Trials
-
Aug 14, 2026, 15:44Scott Cameron: Understanding Sex Differences in Platelet Biology